View Future GrowthSprint Bioscience 過去の業績過去 基準チェック /46Sprint Bioscienceは、平均年間47.3%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間17% 43.7%収益成長率で 成長しています。 Sprint Bioscienceの自己資本利益率は79.5%であり、純利益率は55.2%です。主要情報47.32%収益成長率58.11%EPS成長率Biotechs 業界の成長-14.59%収益成長率43.72%株主資本利益率79.49%ネット・マージン55.18%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.すべての更新を表示Recent updatesお知らせ • Apr 10Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026, at 15:00 W. Europe Standard Time. Location: sprint biosciences premises at novum, halsovagen 7, 141 57 huddinge, Swedenお知らせ • Mar 18Sprint Bioscience AB (publ) Presents New Preclinical Data On Dcps Program At The Aacr Annual MeetingSprint Bioscience AB (publ) announced that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.お知らせ • Apr 05Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025, at 15:00 W. Europe Standard Time. Location: at sprint bioscience`s, premises, at novum Swedenお知らせ • Dec 18Sprint Bioscience AB (Publ) Adds New Cancer Drug Program to PortfolioSprint Bioscience AB (publ) announced that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet. The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals. The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs. AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes. Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals.Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Buying Opportunity • Jul 24Now 36% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be €0.036, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.Buying Opportunity • Jun 17Now 29% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.Buying Opportunity • May 31Now 24% undervaluedOver the last 90 days, the stock is up 9.4%. The fair value is estimated to be €0.052, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.6%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has grown by 31%.Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.Reported Earnings • Aug 25Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)Second quarter 2022 results: kr0.45 loss per share. Revenue: kr24.0k (up 100% from 2Q 2021). Net loss: kr17.9m (loss widened 29% from 2Q 2021).Reported Earnings • May 13First quarter 2022 earnings released: kr0.36 loss per share (vs kr0.65 loss in 1Q 2021)First quarter 2022 results: kr0.36 loss per share. Revenue: kr53.0k (down 87% from 1Q 2021). Net loss: kr14.2m (loss widened 3.7% from 1Q 2021).お知らせ • May 08Sprint Bioscience Launches NIMA at BIO InternationalSprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16.Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Director Rune Nordlander is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 18Full year 2021 earnings released: kr0.85 loss per share (vs kr2.55 loss in FY 2020)Full year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.0m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Over the next year, revenue is expected to shrink by 5.8% compared to a 44% growth forecast for the pharmaceuticals industry in Germany.Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.1m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 5.9% compared to a 59% growth forecast for the pharmaceuticals industry in Germany.Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr33.9m (up 399% from 3Q 2020). Net income: kr17.6m (up kr23.6m from 3Q 2020). Profit margin: 52% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.お知らせ • Sep 08Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project PortfolioSprint Bioscience AB (publ) announces that the company is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer. An important aspect of the development of a tumor is that the cancer cells can affect their environment to facilitate the growth of the tumor. This environment is called the tumor microenvironment and differs from the environment around the healthy cells in the body. The ability of cancer cells to reprogram the healthy cells present in the tumor facilitates tumor growth and can inhibit the body's immune system. The NIMA program focuses on a target protein that produces metabolites that are important for this reprogramming of the tumor's microenvironment. Sprint Bioscience develops inhibitors of this target protein to restore balance and thereby prevent the growth of cancer cells while increasing the immune system's ability to attack them. High levels of the current target protein have been found in tumors from, amongst others, ovarian cancer, breast cancer, and colorectal cancer. Patients with high levels of this protein have a poorer prognosis.Reported Earnings • Aug 18Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr12.0k (down 100% from 2Q 2020). Net loss: kr13.9m (loss widened 11% from 2Q 2020).Reported Earnings • May 14First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: kr408.0k (down 93% from 1Q 2020). Net loss: kr13.7m (loss widened 40% from 1Q 2020).お知らせ • Apr 10Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in fundingSprint Bioscience AB (publ) (OM:SPRINT) announced a private placement of 4,061,510 shares at an issue price SEK 5.10 per share for gross proceeds of SEK 20,713,701 on April 8, 2021. The transaction included participation from new and existing investors.Executive Departure • Mar 03Interim Chief Executive Officer Charlotte Leife has left the companyOn the 1st of March, Charlotte Leife's tenure as Interim Chief Executive Officer of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Charlotte's name. Charlotte is the only executive to leave the company over the last 12 months. Under Charlotte's leadership, the company delivered a total shareholder return of -1.3%.お知らせ • Feb 26Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte LeifeSprint Bioscience AB (publ) announced that Erik Kinnman has been appointed as new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021. Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive). Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank.Is New 90 Day High Low • Feb 21New 90-day low: €0.63The company is down 17% from its price of €0.76 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.Analyst Estimate Surprise Post Earnings • Feb 20Revenue beats expectationsRevenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 62%, compared to a 50% growth forecast for the Biotechs industry in Germany.Reported Earnings • Feb 19Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr19.6m (down 42% from FY 2019). Net loss: kr42.8m (loss widened 99% from FY 2019).Is New 90 Day High Low • Feb 03New 90-day low: €0.68The company is down 10.0% from its price of €0.76 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.Reported Earnings • Nov 02Third quarter 2020 earnings released: kr0.36 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr6.79m (up 55% from 3Q 2019). Net loss: kr5.99m (loss narrowed 17% from 3Q 2019).収支内訳Sprint Bioscience の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:5JA1 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 261538455031 Dec 251679256030 Sep 2550-2656030 Jun 2560-2257031 Mar 2562-2155031 Dec 2466-1856030 Sep 2461-1953030 Jun 24861552031 Mar 2470948031 Dec 2352045030 Sep 2340-1045030 Jun 230-5244031 Mar 230-5847031 Dec 220-6047030 Sep 221-6048030 Jun 2235-3051031 Mar 2235-2649031 Dec 2135-2549030 Sep 2135-2549030 Jun 218-4846031 Mar 2114-4745031 Dec 2019-4346030 Sep 2023-3947030 Jun 2021-4048031 Mar 2035-2348031 Dec 1934-2245030 Sep 1921-3142030 Jun 1919-3341031 Mar 193-4739031 Dec 1818-3239030 Sep 1831-1937030 Jun 1832-1535031 Mar 1841-534031 Dec 1733-1132030 Sep 1741-130030 Jun 1747531031 Mar 1753831031 Dec 1647530030 Sep 1640-230030 Jun 1634-528031 Mar 1617-1425031 Dec 1513-1523030 Sep 1510-1520030 Jun 156-15160質の高い収益: 5JA1は 高品質の収益 を持っています。利益率の向上: 5JA1過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 5JA1過去 5 年間で収益を上げており、収益は年間47.3%増加しています。成長の加速: 5JA1は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: 5JA1昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 45% ) と比較することは困難です。株主資本利益率高いROE: 5JA1の 自己資本利益率 ( 79.5% ) は 傑出している と考えられます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 15:14終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sprint Bioscience AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Siri LadowDanske BankFredrik ThorRedeye
Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
お知らせ • Apr 10Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026, at 15:00 W. Europe Standard Time. Location: sprint biosciences premises at novum, halsovagen 7, 141 57 huddinge, Sweden
お知らせ • Mar 18Sprint Bioscience AB (publ) Presents New Preclinical Data On Dcps Program At The Aacr Annual MeetingSprint Bioscience AB (publ) announced that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.
お知らせ • Apr 05Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025, at 15:00 W. Europe Standard Time. Location: at sprint bioscience`s, premises, at novum Sweden
お知らせ • Dec 18Sprint Bioscience AB (Publ) Adds New Cancer Drug Program to PortfolioSprint Bioscience AB (publ) announced that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet. The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals. The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs. AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes. Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals.
Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Buying Opportunity • Jul 24Now 36% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be €0.036, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.
Buying Opportunity • Jun 17Now 29% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.
Buying Opportunity • May 31Now 24% undervaluedOver the last 90 days, the stock is up 9.4%. The fair value is estimated to be €0.052, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.
Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.6%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has grown by 31%.
Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Aug 25Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)Second quarter 2022 results: kr0.45 loss per share. Revenue: kr24.0k (up 100% from 2Q 2021). Net loss: kr17.9m (loss widened 29% from 2Q 2021).
Reported Earnings • May 13First quarter 2022 earnings released: kr0.36 loss per share (vs kr0.65 loss in 1Q 2021)First quarter 2022 results: kr0.36 loss per share. Revenue: kr53.0k (down 87% from 1Q 2021). Net loss: kr14.2m (loss widened 3.7% from 1Q 2021).
お知らせ • May 08Sprint Bioscience Launches NIMA at BIO InternationalSprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16.
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Director Rune Nordlander is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 18Full year 2021 earnings released: kr0.85 loss per share (vs kr2.55 loss in FY 2020)Full year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.0m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Over the next year, revenue is expected to shrink by 5.8% compared to a 44% growth forecast for the pharmaceuticals industry in Germany.
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.1m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 5.9% compared to a 59% growth forecast for the pharmaceuticals industry in Germany.
Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr33.9m (up 399% from 3Q 2020). Net income: kr17.6m (up kr23.6m from 3Q 2020). Profit margin: 52% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
お知らせ • Sep 08Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project PortfolioSprint Bioscience AB (publ) announces that the company is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer. An important aspect of the development of a tumor is that the cancer cells can affect their environment to facilitate the growth of the tumor. This environment is called the tumor microenvironment and differs from the environment around the healthy cells in the body. The ability of cancer cells to reprogram the healthy cells present in the tumor facilitates tumor growth and can inhibit the body's immune system. The NIMA program focuses on a target protein that produces metabolites that are important for this reprogramming of the tumor's microenvironment. Sprint Bioscience develops inhibitors of this target protein to restore balance and thereby prevent the growth of cancer cells while increasing the immune system's ability to attack them. High levels of the current target protein have been found in tumors from, amongst others, ovarian cancer, breast cancer, and colorectal cancer. Patients with high levels of this protein have a poorer prognosis.
Reported Earnings • Aug 18Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr12.0k (down 100% from 2Q 2020). Net loss: kr13.9m (loss widened 11% from 2Q 2020).
Reported Earnings • May 14First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: kr408.0k (down 93% from 1Q 2020). Net loss: kr13.7m (loss widened 40% from 1Q 2020).
お知らせ • Apr 10Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in fundingSprint Bioscience AB (publ) (OM:SPRINT) announced a private placement of 4,061,510 shares at an issue price SEK 5.10 per share for gross proceeds of SEK 20,713,701 on April 8, 2021. The transaction included participation from new and existing investors.
Executive Departure • Mar 03Interim Chief Executive Officer Charlotte Leife has left the companyOn the 1st of March, Charlotte Leife's tenure as Interim Chief Executive Officer of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Charlotte's name. Charlotte is the only executive to leave the company over the last 12 months. Under Charlotte's leadership, the company delivered a total shareholder return of -1.3%.
お知らせ • Feb 26Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte LeifeSprint Bioscience AB (publ) announced that Erik Kinnman has been appointed as new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021. Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive). Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank.
Is New 90 Day High Low • Feb 21New 90-day low: €0.63The company is down 17% from its price of €0.76 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
Analyst Estimate Surprise Post Earnings • Feb 20Revenue beats expectationsRevenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 62%, compared to a 50% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Feb 19Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr19.6m (down 42% from FY 2019). Net loss: kr42.8m (loss widened 99% from FY 2019).
Is New 90 Day High Low • Feb 03New 90-day low: €0.68The company is down 10.0% from its price of €0.76 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
Reported Earnings • Nov 02Third quarter 2020 earnings released: kr0.36 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr6.79m (up 55% from 3Q 2019). Net loss: kr5.99m (loss narrowed 17% from 3Q 2019).